Plasma concentrations of teicoplanin will be measured in critically ill patients requirirng teicoplanin treatment for severe infection (proven or suspected infection with methicillin-resistant staphylococci) as well as continuous veno-venous hemofiltration for renal failure or albumin dialysis for cholestatic liver failure.
Conditions
Interventions
Trade Name: Targocid
Product Name: Targocid (Teicoplanin)
Pharmaceutical Form: Concentrate for solution for infusion
Sponsors
Medical University, Dpt. Internal Medicin, Division of General Inteal Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Indication for teicoplanin and treatment with teicoplanin Need for CVVH or AD, treatment with CVVH/AD Need for arterial line (mechanical ventilation, hemodynamic instability) Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Age below 18 years lacking indicaltion (contra-indication) for teicoplanin lacking indication for CVVH/AD lacking indication for arterial line lacking consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To determin pharmacokinetics of teicoplanin in criticall ill patients undergoing veno-venous hemofiltration (CVVH) and in patients undergoing albumin dialysis (AD);Secondary Objective: To provide dose recommendations for teicoplanin in criticall ill patients undergoing veno-venous hemofiltration (CVVH) and in patients undergoing albumin dialysis (AD);Primary end point(s): Pharmacokinetics of teicoplanin in patients on CVVH/AD: Cmax, area under the time conentration curve (AUC), Cmin, Kel, T 1/2, V distrib., Clearance | — |
Countries
Austria
Outcome results
None listed